BROADWAY (Follow-up)
A Placebo-Controlled, Double-Blind,
Randomized Phase 3 Study to Evaluate the Effect of 10 mg
Obicetrapib in Participants With Underlying HeFH and/or
ASCVD and LDL-C
>70 and <100 mg/dL Who are Not Adequately Controlled by Their
Lipid-Modifying Therapies
- Medicine
- Obicetrapib
- Population
- ASCVD
- Phase
- III
- Starting year
- 2021